What is it about?
Antibiotic resistance is making bacterial pneumonia increasingly difficult to treat and is driving the search for new ways to prevent and control resistant infections. This review examines emerging strategies that could complement or, in some cases, provide alternatives to conventional antibiotics. These include bacteriophage therapy, mesenchymal stem cells, metal-based nanoparticles, probiotics, herbal medicine, CRISPR-Cas gene-editing technologies, vaccines, and artificial intelligence-supported approaches. We compare how these strategies work, their potential advantages and safety considerations, and how far they have progressed toward clinical application. While several approaches show considerable promise, much of the evidence remains preclinical or early-stage, highlighting the need for stronger clinical research, standardization, regulation, and integration with antimicrobial stewardship.
Featured Image
Photo by Supliful - Supplements On Demand on Unsplash
Why is it important?
Antimicrobial resistance threatens the effectiveness of antibiotics used to treat serious respiratory infections, making new therapeutic and preventive strategies increasingly important. Rather than relying on a single solution, this review brings together multiple emerging approaches to drug-resistant bacterial pneumonia—from highly targeted bacteriophages and CRISPR-Cas technologies to nanoparticles, host-directed therapies, probiotics and vaccination. By comparing their mechanisms, advantages, safety considerations and stages of development, the review helps identify where the strongest opportunities lie and where important evidence gaps remain. Ultimately, tackling antimicrobial resistance will require innovation alongside responsible antibiotic use, surveillance, infection prevention and antimicrobial stewardship.
Perspectives
The future of treating drug-resistant pneumonia is unlikely to depend on discovering a single replacement for antibiotics. Instead, different strategies may play complementary roles: bacteriophages can target specific bacterial pathogens, gene-editing technologies may target resistance mechanisms, nanoparticles may enhance antimicrobial activity, host-directed approaches may strengthen immune responses, and vaccines can prevent infections before antibiotics are needed. What is particularly important, however, is distinguishing scientific promise from clinical readiness. Many of these technologies still require robust clinical trials, standardized protocols and appropriate regulatory frameworks before they can become part of routine patient care.
Dr Dala Daraghmeh
Al-Quds University
Read the Original
This page is a summary of: Advancements in alternative approaches to address antimicrobial resistance in bacterial pneumonia: a comprehensive review, Frontiers in Microbiology, November 2025, Frontiers,
DOI: 10.3389/fmicb.2025.1704931.
You can read the full text:
Contributors
The following have contributed to this page
